Other
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Insmed Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation increased by 107.6% to $71.74M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 147.3%, from -$151.78M to $71.74M. Over 2 years (FY 2022 to FY 2024), Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation shows a downward trend with a -54.9% CAGR.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2017
Last reportedQ1 2026May 7, 2026
Metric ID:
other_cash_cash_equivalents_restricted_cash_and_restrict_8b4577Historical Data
17 periods
| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $518.58M | -$201.08M | -$99.63M | -$1.45M | $659.4M | -$105.13M | -$356.03M | -$125.77M | -$4.74M | $113.36M | $651.07M | -$785.35M | $93.58M | -$151.78M | $881.08M | -$949.56M | $71.74M |
| QoQ Change | — | -138.8% | +50.5% | +98.5% | >999% | -115.9% | -238.7% | +64.7% | +96.2% | >999% | +474.4% | -220.6% | +111.9% | -262.2% | +680.5% | -207.8% | +107.6% |
| YoY Change | — | — | -119.2% | — | — | +47.7% | -257.4% | <-999% | -100.7% | +207.8% | +282.9% | -524.4% | >999% | -233.9% | +35.3% | -20.9% | +147.3% |
Range-$949.56M – $881.08M
CAGR-39.0%
Avg YoY Growth-543.4%
Median YoY Growth-20.9%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Insmed's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- Insmed (INSM) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $71.74M in Q1 2026.
- How has Insmed's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
- Insmed's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation increased by 147.3% year-over-year, from -$151.78M to $71.74M.
- What is the long-term trend for Insmed's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- Over 2 years (2022 to 2024), Insmed's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation has grown at a -54.9% compound annual growth rate (CAGR), from $357.25M to $72.66M.